DD202017A5 - Verfahren zur herstellung von calciumoxaprozin - Google Patents

Verfahren zur herstellung von calciumoxaprozin Download PDF

Info

Publication number
DD202017A5
DD202017A5 DD82239350A DD23935082A DD202017A5 DD 202017 A5 DD202017 A5 DD 202017A5 DD 82239350 A DD82239350 A DD 82239350A DD 23935082 A DD23935082 A DD 23935082A DD 202017 A5 DD202017 A5 DD 202017A5
Authority
DD
German Democratic Republic
Prior art keywords
oxaprozin
calcium
salt
water
sodium
Prior art date
Application number
DD82239350A
Other languages
German (de)
English (en)
Inventor
Ahmed S Mughal
Original Assignee
Wyeth John & Brother Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth John & Brother Ltd filed Critical Wyeth John & Brother Ltd
Publication of DD202017A5 publication Critical patent/DD202017A5/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DD82239350A 1981-04-28 1982-04-27 Verfahren zur herstellung von calciumoxaprozin DD202017A5 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8113074 1981-04-28

Publications (1)

Publication Number Publication Date
DD202017A5 true DD202017A5 (de) 1983-08-24

Family

ID=10521427

Family Applications (1)

Application Number Title Priority Date Filing Date
DD82239350A DD202017A5 (de) 1981-04-28 1982-04-27 Verfahren zur herstellung von calciumoxaprozin

Country Status (24)

Country Link
US (2) US4465838A (sh)
EP (1) EP0063884B1 (sh)
JP (1) JPS57181072A (sh)
KR (1) KR880000871B1 (sh)
AT (1) ATE14015T1 (sh)
AU (1) AU544975B2 (sh)
CA (1) CA1169867A (sh)
CS (1) CS236674B2 (sh)
DD (1) DD202017A5 (sh)
DE (1) DE3264400D1 (sh)
DK (1) DK150604C (sh)
ES (1) ES8307230A1 (sh)
FI (1) FI71314C (sh)
GR (1) GR75913B (sh)
HU (1) HU185276B (sh)
IE (1) IE52909B1 (sh)
IL (1) IL65443A (sh)
MY (1) MY8700599A (sh)
NZ (1) NZ200247A (sh)
PH (1) PH18053A (sh)
PL (1) PL136322B1 (sh)
PT (1) PT74794B (sh)
ZA (1) ZA822355B (sh)
ZW (1) ZW7482A1 (sh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5380738A (en) * 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US6726928B2 (en) * 1994-10-28 2004-04-27 R.P. Scherer Technologies, Inc. Process for preparing solid dosage forms for unpalatable pharmaceuticals
DE69733752T2 (de) * 1996-05-20 2006-06-01 G.D. Searle Llc, Chicago Arzneimittel enthaltend oxaprozin-natriumsalz,-kaliumsalz, oder-tris(hydroxymethyl)aminomethansalz
US7358254B2 (en) * 2001-07-13 2008-04-15 Bristol-Myers Squibb Company Method for treating atherosclerosis employing an aP2 inhibitor and combination
AU2006228869A1 (en) * 2005-03-30 2006-10-05 Astion Pharma A/S Oxaprozin or a closely related compound for the treatment of eczema
US20060229347A1 (en) * 2005-03-30 2006-10-12 Astion Development A/S Treatment of eczemas
CN102197163B (zh) * 2008-08-26 2014-03-05 多尔夫凯塔尔化学制品（I）私人有限公司 一种用于抑制酸腐蚀的新型添加剂及其使用方法
KR20140065862A (ko) * 2012-11-22 2014-05-30 에스케이케미칼주식회사 발포성 속붕해성 이매티닙 제제

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1206403A (en) * 1966-12-15 1970-09-23 Wyeth John & Brother Ltd Oxazoles
GB1245087A (en) * 1967-10-26 1971-09-02 Wyeth John & Brother Ltd Heterocyclic compounds
US3578671A (en) * 1967-11-06 1971-05-11 Wyeth John & Brother Ltd Oxazoles

Also Published As

Publication number Publication date
CA1169867A (en) 1984-06-26
HU185276B (en) 1984-12-28
JPS57181072A (en) 1982-11-08
DE3264400D1 (en) 1985-08-01
ZW7482A1 (en) 1983-11-09
CS236674B2 (en) 1985-05-15
PL136322B1 (en) 1986-02-28
IE52909B1 (en) 1988-04-13
GR75913B (sh) 1984-08-02
IL65443A (en) 1985-04-30
FI71314C (fi) 1986-12-19
ATE14015T1 (de) 1985-07-15
NZ200247A (en) 1984-10-19
AU544975B2 (en) 1985-06-27
KR830009772A (ko) 1983-12-23
JPH0261466B2 (sh) 1990-12-20
FI821324A0 (fi) 1982-04-15
IE820766L (en) 1982-10-28
US4465838A (en) 1984-08-14
ES511730A0 (es) 1983-07-01
PT74794A (en) 1982-05-01
PH18053A (en) 1985-03-18
DK150604C (da) 1987-12-07
EP0063884A1 (en) 1982-11-03
PL236145A1 (sh) 1982-12-06
ES8307230A1 (es) 1983-07-01
AU8237882A (en) 1982-11-04
PT74794B (en) 1983-11-07
FI821324L (fi) 1982-10-29
US4532253A (en) 1985-07-30
IL65443A0 (en) 1982-07-30
MY8700599A (en) 1987-12-31
DK150604B (da) 1987-04-13
DK183582A (da) 1982-10-29
FI71314B (fi) 1986-09-09
KR880000871B1 (ko) 1988-05-28
ZA822355B (en) 1983-11-30
EP0063884B1 (en) 1985-06-26

Similar Documents

Publication Publication Date Title
DE3915347C2 (de) Harzadsorbate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Präparate
DE69110592T2 (de) Pharmazeutische Zubereitung mit verbessertem Geschmack, poröse Partikel enthaltend, und deren Herstellungsmethode.
EP0126379B1 (de) Zweiphasenformulierung
DE69925016T2 (de) Verbesserte tablette mit schneller auflösbarkeit
CH655850A5 (de) Medizinisches praeparat enthaltend pirprofen.
DE2907215A1 (de) Feste depotarzneimittelpraeparate und verfahren zu deren herstellung
DE2020620A1 (de) Traeger fuer das unmittelbare Komprimieren von Tabletten
WO1997004754A1 (de) Kautablette mit brausewirkung
DE2706660A1 (de) Ascorbinsaeure enthaltende granulate und verfahren zu ihrer herstellung
DD202017A5 (de) Verfahren zur herstellung von calciumoxaprozin
DE3019032C2 (de) Antacider Wirkstoff auf Magnesium-Aluminiumhydroxid-Basis, seine Herstellung und Verwendung
EP0186090B1 (de) Verfahren zur Herstellung von Ascorbinsäure-Granulat
EP0058410A1 (de) Acesulfamhaltige Zusammensetzung, Tabletten auf Basis dieser Zusammensetzung und Verfahren zu ihrer Herstellung
DE69524226T2 (de) Verfahren zum herstellen von fusidinsäuretabletten
DE1937133C3 (de) Verwendung von Aluminium-, Calcium- oder Magnesiummono-, -di- oder -tristearat
EP0164587A2 (de) Nifedipinpräparate und Verfahren zu ihrer Herstellung
DE963270C (de) Verfahren zur Herstellung von Tabletten
DE2311552A1 (de) Extrakte von pflanzen der gattung avena enthaltende praeparate in tablettenoder granulatform
DE69100053T2 (de) Arzneimittelzusammensetzung in stabiler wässriger Suspensionsform auf der Basis von Sucralfat und einem Antacidum sowie Verfahren zu ihrer Herstellung.
DE2951132C2 (sh)
DE881568C (de) Verfahren zur Herstellung von Metallpektinverbindungen zur therapeutischen Verwendung
DE1068701B (de) Verfahren zur Herstellung von antibiotisch wirksamem Tetracyclinnatriumhexametaphosphat
DE1179336B (de) Roentgenkontrastmittel
CH684929A5 (de) Ibuprofen-haltige Brausezusammensetzung und ihre Herstellung.
DE2100269C3 (sh)

Legal Events

Date Code Title Description
ENJ Ceased due to non-payment of renewal fee